Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against AstraZeneca PLC. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is AstraZeneca PLC (AZN) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AstraZeneca PLC (“AstraZeneca” or “the Company”) (NYSE: AZN). Investors who purchased AstraZeneca securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether AstraZeneca has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On July 9, 2026, AstraZeneca disclosed that the late-stage Phase-3 CARDIO-TTransform trial of Wainua, an amyloid cardiomyopathy treatment developed in collaboration with Ionis Pharmaceuticals, did not meet its primary endpoint. Following this news, AstraZeneca’s American Depositary Share (“ADS”) price fell $10.79 per ADS, or 5.7%, to close at $187.49 per ADS on July 9, 2026.
What Should AstraZeneca PLC (AZN) Investors Do?
If you are aware of any facts relating to this investigation or purchased AstraZeneca securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
How Is AstraZeneca PLC (NYSE: AZN) Stock Trading Today?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”